[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 281
Citations 0
Correction
July 2016

Incorrect Term in the Methods and Discussion

JAMA Ophthalmol. 2016;134(7):849. doi:10.1001/jamaophthalmol.2016.2062

In the Original Investigation entitled “Quantification of Ellipsoid Zone Changes in Retinitis Pigmentosa Using en Face Spectral Domain–Optical Coherence Tomography” published online March 31, 2016, and in the June print issue of JAMA Ophthalmology,1 an incorrect term was used in 2 places in the text. In the Description of the Cohort subsection of the Methods section, the first sentence, which read, “The Trial of Oral Valproic Acid for Retinitis Pigmentosa11 is a phase 2 multiple-site, randomized, placebo-controlled clinical trial of the safety and efficacy of valproic acid for autosomal recessive RP.” should be replaced with “The Trial of Oral Valproic Acid for Retinitis Pigmentosa11 is a phase 2 multiple-site, randomized, placebo-controlled clinical trial of the safety and efficacy of valproic acid for autosomal dominant RP.” In the Discussion section, the first sentence, which read, “In this study, we evaluated a method to measure the EZ area from en face SD-OCT images obtained from the eyes of patients with autosomal recessive RP.” should be replaced with “In this study, we evaluated a method to measure the EZ area from en face SD-OCT images obtained from the eyes of patients with autosomal dominant RP.” This article was corrected online and in the print issue.

References
1.
Hariri  AH, Zhang  HY, Ho  A,  et al; Trial of Oral Valproic Acid for Retinitis Pigmentosa Group.  Quantification of ellipsoid zone changes in retinitis pigmentosa using en face spectral domain–optical coherence tomography [published online March 31, 2016]. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2016.0502.
×